Introduction
Karten and Rivier [1] published a com prehen sive review o f the design o f G nR H analogs, sum marized rationales, perspectives, and structurefunction relationships and emphasized the timely importance of negating the release of histamine by such antagonists.
Nestor et al. [2] reported on the synthesis o f a new series o f unnatural amino acids, N, N-dialkyl-D-homoargines, and their use in synthesis o f an tagonists of LH R H . Rivier et al. [3] designed and synthesized a series of cyclic peptides which showed antagonism. D-Citrulline and D-homocitrulline were incorporated in analogs in position 6 by Bajusz et al. [4] , Reductive alkylation of D -L y s 6 was used for further modifications in positions 6 by H ocart et al. [5] .
An antagonist, named Antide, had effective potency and negligible histamine release, [ N -A c -D 2 N a l \ DpClPhe2, D 3 P a l3, NicLys5, DNicLys6, ILys8, D A la10]-L H R H , was designed and synthesized by Ljungqvist et al. (6 -7 ) . Antide has been scaled up and is under pharmacological evaluation for exploratory clinical testing. [7] , had higher antiovulatory activity than Antide, i.e. 73%/0.25 jig and 100%/ 0.5 jig vs. 36%/0.5 jig and 100%/1.0 jig for Antide.
We describe herein antagonists of LHRH with emphasis upon the modification o f substitutes in position 10 with D -A la , Sar, D -S e r. desGly N H E t, D -A b u , Gly, D -F 2Ala and with various substitutions in positions 5, 6, and 8.
Experimental

Materials
The natural amino acids were obtained from Peninsula Laboratories, San Carlos, CA. B o c-D -2 N a l, B o c -D -3 P a l, B o c -D -p C lP h e and BocILys(Z) DCHA salt were provided by Dr. Narasim ha Rao of the Southwest Foundation for Biomedical Research, San Antonio, TX. The un natural amino acids were synthesized using stand ard procedures. The nature of productive groups, solvents and other chemicals were the same as de scribed [8] .
Synthesis
All of the peptides were synthesized by the Merrifield solid-phase method. Decapeptide analogues were synthesized on the benzhydrylamine (BHA) resin hydrochloride, as described [6, 8] . A nonpep-tide ethyl amide analogue was synthesized on a chloromethyl-polystyrene-1% divinyl benzyne resin as described [9] .
Purification and purity
M ost of the peptides were purified by silica gel chrom atography with the solvent systems «-butanol-acetic acid-water 4:1:2 or «-butanolpyridine-acetic acid-water 4:1:1:2 followed by gel filtration on Sephadex G25 with 6% acetic acid. Alternatively, purification was achieved by gel fil tration on Sephadex G 25 followed by chrom atog raphy on Sephadex LH 20 with the solvent system water-/7-butanol-acetic acid-methanol 90:10:10:8. The purity was checked by HPLC, TLC and ami no acid analysis. HPLC was performed on a W a ters instrum ent equipped with a model 660 solvent program m er and either a //-Bondapak C 18 or Vydac C l8 analytical column. Single peaks were obtained at flow rates of 2.0 or 1.5 ml/min using linear gradients of increasing acetonitrile in 0.01 M K H 2P 0 4. pH 3.0.
TLC was done on EM 0.25 mm Silica gel plates and single spots were observed in at least four different solvent systems as determined by the chlorine-o-tolidine test.
The am ino acid analyses were carried out on a Beckman 118 CL amino acid analyzer after hydro lysis at 110°C in constant-boiling HC1 for 24 h. U nnatural am ino acids were verified and with the exception o f 3-Pal not quantified. All values for amino acid ratios were correct within the limits of experimental error.
Biological assays
The AO A in rats [10] and the Wheal test [6] were determined and described.
Results and Discussion
The data in Table I The first three peptides in Table I Abbreviations: N ie L y s = N e -N ie o tin o y lly s in e . P ieL ys = N s -P ic o lin o y lly sin e , IL ys = N e -iso p ro p y ly sin e , p C L p h e = 4 -C h lo ro p h e n y la la n in e , 2 -N a l = 3 -(2 -n ap h th y l) a la n in e , 3-P al = 3 -(3 -p y rid y l) a la n in e , P z A C A la = 3-(4-p y razin y lc a rb o n y la m in o c y c lo h e x y l) a la n in e , A b u = 2 -a m in o b u ty ric a cid , S a r = sa rco sin e, N -m e th y lg ly cin e, F 2A la = 3 -d iflu o ro a la n in e .
antagonist with highest potency is analog 1 with D -A la 10, which showed 60% AOA at 0.125/ig, 85% AOA at 0.25 jug. D -A la 10 in analog 1 was re placed by the isomeric Sar, which has an N-Methyl group. Analog 2, with S ar10 was inactive at 0.25 jug. For this sequence, Sar is a very detrim en tal substituent in position 10. The exchange of D -A la 10 in analog 1 by G ly10 in analog 3 reduced the potency from 85% to 11 % at 0.25 jug.
Analog 4 has PicLys5, cw -D -PzA C Ä la6, ILys8, D A la10 and showed 73% AOA at 0.25 jug [7] , The introduction of (desGly10, NHEt), which may pro tect the peptide from a "post-proline" cleaving enzyme, caused a decrease in potency from 73% to 25% AOA at 0.25 jig, and from 100% to 22% AOA at 0.5 jig. The C-terminal ethylamide group, which had resulted in improved potency in an agonist series of analogs [11] was not beneficial for T a b le II. C h ro m a to g ra p h ic d a ta o n L H R H a n ta g o n ists* .
A n a lo g N o .
H L P C L in e a r G ra d ie n t % c h a n g e o f C H^C N T L C R e te n tio n T im e (m in ) R f l R f2 R f3 R f4 R f5 T a b le III. A m in o a cid a n aly sis o f L H R H a n ta g o n is ts .
A n a lo g N o .* Ser P ro A la L eu T y r L ys A rg Ile IL ys G ly 2-N al p C lp h e 3-P al A C A la o th ers* * 
